Faeth Therapeutics (FTH) EBITDA (2020 - 2026)

Faeth Therapeutics (FTH) has reported EBITDA for 7 consecutive years, with -$18.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 253.15% year-over-year to -$18.4 million; the trailing twelve-month figure through Jun 2026 stood at -$198.8 million (down 595.73% YoY), and the FY2025 full-year result was -$22.3 million, up 31.66% from the prior year.
• EBITDA rose to -$18.4 million in Q2 2026 per FTH's latest filing, from -$170.6 million in the prior quarter.
• Across five years, EBITDA topped out at -$4.9 million in Q3 2025 and bottomed at -$170.6 million in Q1 2026.
• Historically, EBITDA has averaged -$18.4 million across 5 years, with a median of -$8.5 million in 2024.
• The sharpest annual moves came in 2023 and 2026: EBITDA soared 44.5% in 2023, then plunged 2245.71% in 2026.
• Over 5 years, EBITDA stood at -$13.0 million in 2022, then jumped by 37.6% to -$8.1 million in 2023, then retreated by 1.62% to -$8.3 million in 2024, then soared by 40.09% to -$5.0 million in 2025, then plunged by 270.89% to -$18.4 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$18.4 million, -$170.6 million, and -$5.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.